‘Children with cancer cannot wait’: the human cost of clinical trial delays after Brexit

Exclusive: Price of importing drugs for a Paris and Birmingham study has almost quadrupled to 175,000

• NHS cancer patients denied life-saving drugs due to Brexit costs, report finds

Children are among the NHS patients being denied access to revolutionary cancer drugs as a result of red tape and extra costs caused by Brexit, according to a report leaked to the Guardian.

Two examples illustrate how the UK's departure from the EU is derailing UK cancer research, leaving patients in limbo and unable to access pioneering treatments.

eSMART is a trial of new targeted drugs and chemotherapy for children, teenagers and young adults whose cancer has returned or treatment has stopped working.